Material Agreement (Form 8-K)

Item 1.01 Entry into a Material Definitive Agreement.

On April 2, 2026, Advanced Biomed Inc. (the "Company") entered into a Share Purchase Agreement (the "Agreement") with Acellent Technologies (Hong Kong) Co. Limited (the "Target") and the sole shareholder of the Target (the "Seller"), pursuant to which the Company agreed to purchase from Seller 100% of the equity interest in the Target (the "Acquisition").

The Target is a company incorporated under the laws of Hong Kong and is engaged in providing AI-powered financial verification and audit solutions.

Pursuant to the Agreement, Seller agreed to sell, convey, assign, transfer and deliver to the Company, and the Company agreed to purchase from Seller, 100% of the equity interest in the Target for a total purchase price of 270,000 shares of the Company's common stock, par alue $0.001 per share (the "Common Stock"), with an estimated value of $4.00 per share and an aggregate estimated value of $1,080,000. The closing of the transaction is conditioned upon (i) the completion of financial and legal due diligence reviews of the Target and (ii) receipt of any and all regulatory approvals required in connection with the Acquisition.

The foregoing description of the Agreement does not purport to be complete and is qualified in its entirety by reference to the complete text of the Agreement, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.